

Report of the First Meeting of the Pandemic Influenza Preparedness (PIP) Framework 2016 Review Group

ORGANIZATION AND PROCESS OF THE MEETING

1. The first meeting of the Review Group was held by teleconference on 7 January 2016, 12h00-14h00 Central European Time (CET), with the following agenda:
 1. Welcome from the WHO Secretariat
 2. Opening
 - Introductions
 - Declarations of Interest, confidentiality issues, copyright agreements
 - Selection of Chair
 - Adoption of Agenda
 3. Brief Overview of the PIP Framework and the 2016 Review
 4. Method of Work
 1. Adoption of terms of reference
 2. Expected number of meetings and timeline
 5. Preparation for the next meeting in February
 1. Review the key areas of work and identify challenges to improving implementation of the PIP Framework (possibly dividing into two or three working groups, each with a focal point)
 2. Identify background documents and analysis needed to support the review
 3. Begin to identify key informants for interviews in March
 6. Any other business

WELCOME FROM THE WHO SECRETARIAT AND OPENING OF MEETING

2. Anne Huvos, WHO Secretariat, welcomed the Review Group members.
3. The Secretariat and the Members of the Review Group introduced themselves. All members of the Review Group participated in the meeting (the list of Review Group members is found at Annex 1).
4. Declarations of interest were reviewed by the Secretariat and relevant interests were disclosed. The Statement on Declarations of Interests is available in Annex 2.
5. The Group selected Dr Christine Kaseba-Sata as the Chair. The Chair welcomed the participants in the teleconference and outlined the agenda.
6. The Group adopted the agenda without modification.

OVERVIEW OF THE PIP FRAMEWORK AND THE 2016 REVIEW

7. The Secretariat presented an overview of the PIP Framework background and implementation milestones and challenges.
8. The Review Group discussed many elements of the presentation and requested that the Secretariat prepare background information on key issues.

METHOD OF WORK

9. The Principal Legal Officer provided an overview of the draft Terms of Reference. It was explained that the Terms of Reference are drawn from the Report of the PIP Advisory Group Special Session, 13-14 October 2015, which was accepted by the Director-General. The Report has been shared with Member States as part of the Secretariat's report to the upcoming session of the WHO Executive Board.¹
10. The Review Group considered that it would be useful to look at the impact of the PIP Framework beyond influenza pandemic preparedness and suggested that the Terms of Reference be amended to reflect this.
11. The Review Group adopted its Terms of Reference (see Annex 3).
12. The Secretariat presented a draft timeline of meetings. It was proposed that there be five meetings – three face-to-face with stakeholders and two teleconferences, on the understanding that additional teleconferences could be scheduled as needed.

¹ See: http://apps.who.int/gb/ebwha/pdf_files/EB138/B138_21Add1-en.pdf

13. The Secretariat proposed a timeline as follows:

<i>17 Feb 2016</i>	Second meeting of the Review Group by WebEx teleconference. Closed meeting.
<i>30 Mar- 1 Apr 2016</i>	Third meeting of the Review Group in Geneva. The meeting will include open sessions for consultations with Member States and stakeholders, as well as closed sessions for Review Group only.
<i>June 2016, Date TBD</i>	Fourth meeting of the Review Group meeting in Geneva. Closed meeting.
<i>September 2016 Date TBD</i>	Fifth meeting of the Review Group (if required) in Geneva. The meeting will include open sessions for consultations with Member States and stakeholders, as well as closed sessions for Review Group only.
<i>31 October 2016</i>	Director-General receives Review Group final Report for submission to Executive Board
<i>Jan 2017</i>	140 th Executive Board considers report
<i>May 2017</i>	70 th World Health Assembly

14. The Group underscored the need for transparency and interaction with Member States and stakeholders. They requested that the Secretariat explore and propose web-based consultations in addition to expert interviews. The Review Group agreed that it would provide regular reports on their progress, including through meeting reports and debriefings after meetings.

15. The Group agreed to establish sub-groups to carry out the work. They divided into three sub-groups to cover the topics outlined in the Terms of Reference, as follows: 1) Virus Sharing, including genetic sequence data; 2) Benefit Sharing; and 3) Governance & Linkages with other instruments.

NEXT STEPS

16. The next meeting of the Review Group will be 17 February by WebEx teleconference

17. Each of the Sub-Groups will prepare for the meeting in February by developing key questions and identifying informants.

18. The Review Group approved the meeting report.

PANDEMIC INFLUENZA PREPAREDNESS (PIP) FRAMEWORK REVIEW GROUP

7 JANUARY 2015

Review Group Members

Review Group Members	Affiliation
Professor William Kwabena Ampofo	Head of Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana
Dr Christine Mwelwa Kaseba-Sata (Chair)	Former WHO Goodwill Ambassador against Gender-based Violence, Zambia
Dr Frances McGrath	Chief Advisor, Clinical Leadership, Protection and Regulation, Ministry of Health, New Zealand
Dr Talat Mokhtari-Azad,	Director, Iranian National Influenza Center
Ms Johanne Newstead	Head of Food Policy, Public Health Directorate, Department of Health, United Kingdom
Dr Theresa Tam	Deputy Chief Public Health Officer of the Public Health Agency of Canada
Dr Viroj Tangcharoensathien	Senior Adviser, International Health Policy Program, Ministry of Public Health, Thailand
Prof Dr Makarim Wibisono	United Nation Special Rapporteur on Palestinian Territories Occupied Since 1967

PIP Review Group meeting

7 January 2016

Summary of Declarations of Interest by members

- In accordance with WHO policy, in advance of this meeting, all experts have been asked to provide a duly completed Declaration of Interests to inform WHO about real, potential, or actual Conflicts of Interest that they might have in relation to the subject matter of this meeting.
- Over the course of this meeting the Review Group will be provided background information on PIP, understand the terms of reference, get an overview of the review process and establish the method of work.

The Review Group experts serve in their individual capacity acting as international experts serving WHO exclusively. The following interests and/or affiliations were disclosed to the Secretariat and are relevant to the subject of the PIP Review Group's work:

Name	Interest declared
Prof William Kwabena Ampofo	Affiliated with a GISRS laboratory
Dr Frances McGrath	Civil Servant
Dr Talat Mokhtar-Azad	Affiliated with a GISRS laboratory
Ms Johanne Newstead	Civil Servant
Dr Theresa Tam	Civil Servant
Dr Viroj Tangcharoensathien	Civil Servant
Prof. Dr. Makarim Wibisono	Civil Servant

No other interests declared by members of the Review Group were deemed relevant to the work of the group.

PIP Framework 2016 Review Group

Terms of Reference

In accordance with WHA 64.5 OP4(2) and Section 7.4.2, the PIP Framework and its annexes are to be reviewed by 2016. To this end, the Director General has established an independent Review Group. The Terms of Reference for the Review Group have been developed based on advice received from Member States, industry and other stakeholders and the PIP Advisory Group.²

Objective

The Review Group will review the PIP Framework and its annexes with a view to proposing revisions reflecting developments as appropriate to the World Health Assembly in 2017, through the Executive Board.

Guiding Principles

The Review Group will undertake its work guided by the following principles:

1. Independence and impartiality
2. Transparency
3. Engagement with Member States & stakeholders
4. Iterative process, providing Member States and stakeholders regular information about the work under way

Scope

The Review should be comprehensive on all aspects of the PIP Framework and assess whether implementation of the PIP Framework is meeting its objectives to: “Improve pandemic influenza preparedness and response, and strengthen the protection against pandemic influenza by improving and strengthening the WHO Global Influenza surveillance and response system “WHO GISRS”, with the objective of a fair, transparent, equitable, efficient, effective system for, on an equal footing:

1. the sharing of H5N1 and other influenza viruses with human pandemic potential;
2. access to vaccines and other benefits”

Key questions

The Report of the PIP Framework Review will answer the following questions:

² See: http://www.who.int/influenza/pip/advisory_group/ag_spec_session_report.pdf?ua=1

- a. What are the achievements since the PIP Framework was adopted?
- b. Has implementation of the PIP Framework improved global pandemic influenza preparedness, including inter-pandemic surveillance, and capacity to respond?
- c. What are the challenges, and possible ways of addressing them?

Topics

The Review Group will pay particular attention to the following sections/topics:

1. Virus Sharing - PIP Framework Section 5

- a) *Sharing of influenza viruses with human pandemic potential*
 - The status of virus sharing through WHO Global Influenza surveillance and response system.
- b) *Genetic Sequence Data*
 - How genetic sequence data should be handled under the PIP Framework. In addressing the Key Questions, the Review Group will consider the reports and other products developed by the Advisory Group.
- c) *Collateral benefits*
 - Have there been other areas which have benefited as a result of virus sharing?

2. Benefit Sharing – PIP Framework Section 6

- a) *Standard Material Transfer Agreements 2*
 - The status of conclusion of Standard Material Transfer Agreements 2, in particular those with vaccine manufacturers.
- b) *Partnership Contribution (PC):*
 - The Partnership Contribution mechanism, including the level of the yearly amounts to be collected, the collection process, and the use of the funds.
- c) *Interactions with manufacturers and other stakeholders:*
 - All topics should include an assessment of interactions with manufacturers and other stakeholders, including information about the role of Regional Offices in the selection of countries to receive support through the PC.
- d) *Collateral benefits*
 - Have there been other areas which have benefited as a result of the benefit sharing?

3. Governance – PIP Framework Section 7 (focusing on sections 7.2.5 to 7.4.1 of the Framework)

4. Linkages with other instruments (the Global Action Plan, International Health Regulations (2005), Nagoya Protocol, etc.)

- The possible synergies with the International Health Regulations (2005) and other programs, and the relationship with other international instruments including the Nagoya Protocol.

Method of work

The Review Group will review background documents prepared by key experts and the Secretariat, and hear testimony from individuals representing all relevant stakeholders. It will be supported in its work by the WHO Review Group Secretariat.

Reporting

The Review Group will regularly provide updates on its work to Member States and Stakeholders.

The Review Group will provide its final report to the Director-General no later than 31 October 2016.